Haloperidol Concentrations in Patients With Alzheimer's Dementia

Maurice W Dysken, Sue B. Johnson, Lori Holden, Govind Vatassery, Julie Nygren, Mary Jelinski, Michael Kuskowski, Larry Schut, J. Riley McCarten, David Knopman, Gabe J. Maletta, Stacy Skare

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


To investigate the relationship between clinical response and haloperidol blood concentrations in Alzheimer's dementia (AD) patients with behavior problems, 29 AD inpatients were assigned to a fixed oral dosage of haloperidol (0.5 mg, 1.0 mg, or 2.0 mg) every 12 hours for 3 weeks. BEHAVE-AD ratings and concentrations of plasma and RBC haloperidol and reduced haloperidol were obtained on Days 8, 15, and 22. Although no significant linear or curvilinear relationships were apparent between percent of change on BEHAVE-AD and plasma or RBC haloperidol concentrations, a good response (change ≥ 30%) was observed in 55% of the patients who entered the study.

Original languageEnglish (US)
Pages (from-to)124-133
Number of pages10
JournalAmerican Journal of Geriatric Psychiatry
Issue number2
StatePublished - 1994
Externally publishedYes

Bibliographical note

Funding Information:
This work was supported by a Merit Review Grant from Department of Veterans Affairs Medical Research.


Dive into the research topics of 'Haloperidol Concentrations in Patients With Alzheimer's Dementia'. Together they form a unique fingerprint.

Cite this